Xeris Pharmaceuticals Aktie

Xeris Biopharma presented its strategic vision, emphasizing growth from Recorlev and a planned phase-3 study for XP8121 in hypothyroidism with gastrointestinal absorption disorders. The company expects revenue growth of around 40% year over year and reports gross margins of about 85% as well as positive adjusted EBITDA in the prior year. Market potential is cited at $1–3 billion for XP8121 and about $1 billion for Recorlev; commercialization is to be driven by expanded sales activities and clinician training. Xeris stresses a self-funded business model but sees competitive pressure in an evolving market. » Więcej na de.investing.com

Xeris Pharmaceuticals stock rose to a 52-week high of $8.02 with a market capitalization of about $1.28 billion; however, technical indicators show an overbought level. In Q2 2025 Xeris beat EPS expectations (-$0.01 vs. -$0.03) and reported revenue of $71.5 million, supported by revenue growth of 35.6% year over year. Xeris Biopharma Holdings also received a new patent for Recorlev through March 2040, and H.C. Wainwright initiated coverage with a buy rating and a $10.00 price target. » Więcej na de.investing.com